Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Eli Lilly and Company Limited
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
An Open-Label Study of Oral Enzastaurin HCI in Patients with Advanced or Metastatic Malignancies
To collect further basic safety data on patients with advanced or metastatic malignancies treated with enzastaurin.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer (Sweden will participate in Phase 2 of this trial, only)
The primary objective of the Phase 1 portion of this study is to determine the MTD of the combination therapy of pemetrexed and carboplatin when administered to patients with platinum-sensitive recurr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited, Indianapolis
MAJ Il y a 5 ans
A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes
Primary objective is to determine if LY2382770, administered monthly for 1 year is more effective than placebo at slowing the progression of diabetic kidney disease in patients treated with angiotensi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention
The primary objective of this study is to test the hypothesis that CS-747 plus aspirin is superior to clopidogrel plus aspirin in the treatment of subjects with acute coronary syndrome who are to unde...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
A Phase 3 Study of Pemetrexed Plus Best Supportive Care versus Best Supportive Care As Maintenance Therapy Immediately Following Induction Treatment For Advanced Non-Small Cell Lung Cancer
The primary objective is to compare maintenance therapy with pemetrexed plus BSC versus placebo plus BSC, in terms of the overall survival time (OS) in patients with Stage IIIB (with pleural effusion ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients with Completely Resected Stage Ib or II Non-Small Cell Lung Cancer
The primary objective of this study is to assess the feasibility of an adjuvant chemotherapy of pemetrexed, in combination with either cisplatin or carboplatin in patients with completely resected sta...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer
Main objective : To compare, in terms of time to progression (TTP) of the brain metastases, maintenance therapy with enzastaurin plus BSC vs. placebo plus BSC in patients with brain metastases from l...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited, UK
MAJ Il y a 5 ans
The Coronary Artery Revascularisation in Diabetes trial
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6